The Journal of Urology
Volume 187, Issue 2 , Pages 508-512, February 2012

Comparison of an Interstitial Cystitis/Bladder Pain Syndrome Clinical Cohort With Symptomatic Community Women From the RAND Interstitial Cystitis Epidemiology Study

  • Katy S. Konkle

      Affiliations

    • University of Michigan Medical Center, Ann Arbor, Michigan
  • ,
  • Sandra H. Berry

      Affiliations

    • RAND Corporation, Santa Monica, California
    • Financial interest and/or other relationship with RAND Corporation (Health Unit).
  • ,
  • Marc N. Elliott

      Affiliations

    • RAND Corporation, Santa Monica, California
  • ,
  • Lara Hilton

      Affiliations

    • RAND Corporation, Santa Monica, California
  • ,
  • Marika J. Suttorp

      Affiliations

    • RAND Corporation, Santa Monica, California
  • ,
  • Daniel J. Clauw

      Affiliations

    • University of Michigan Medical Center, Ann Arbor, Michigan
    • Financial interest and/or other relationship with Cypress Biosciences Inc., Eli Lilly and Company, Forest Laboratories Inc., Jazz Pharmaceuticals Inc., Merck & Co. Inc, Pierre Fabre Pharmaceuticals USA, Pfizer Inc. and UCB Inc.
  • ,
  • J. Quentin Clemens

      Affiliations

    • University of Michigan Medical Center, Ann Arbor, Michigan
    • Financial interest and/or other relationship with Merck, Pfizer, Lilly, Afferent Pharmaceuticals Inc. and United Biosource Inc.
    • Corresponding Author InformationCorrespondence: University of Michigan Medical Center, 3875 Taubman Center, 1500 E. Medical Center Dr., Ann Arbor, Michigan 48109-5330 (telephone: 734-615-1262; FAX: 734-615-9127)

Received 3 June 2011 published online 15 December 2011.

Purpose

The RAND Interstitial Cystitis Epidemiology survey estimated that 2.7% to 6.5% of United States women have urinary symptoms consistent with a diagnosis of interstitial cystitis/bladder pain syndrome. We describe the demographic and clinical characteristics of the symptomatic community based RAND Interstitial Cystitis Epidemiology cohort, and compare them with those of a clinically based interstitial cystitis/bladder pain syndrome cohort.

Materials and Methods

Subjects included 3,397 community women who met the criteria for the RAND Interstitial Cystitis Epidemiology high sensitivity case definition, and 277 women with an interstitial cystitis/bladder pain syndrome diagnosis recruited from specialist practices across the United States (clinical cohort). Questions focused on demographic information, symptom severity, quality of life indicators, concomitant diagnoses and treatment.

Results

Average symptom duration for both groups was approximately 14 years. Women in the clinical cohort reported worse baseline pain and maximum pain, although the absolute differences were small. Mean Interstitial Cystitis Symptom Index scores were approximately 11 for both groups, but mean Interstitial Cystitis Problem Index scores were 9.9 and 13.2 for the clinical cohort and the RAND Interstitial Cystitis Epidemiology cohort, respectively (p <0.001). The RAND Interstitial Cystitis Epidemiology subjects were more likely to be uninsured.

Conclusions

The RAND Interstitial Cystitis Epidemiology community cohort was remarkably similar to an interstitial cystitis/bladder pain syndrome clinical cohort with respect to demographics, symptoms and quality of life measures. In contrast to other chronic pain conditions for which clinical cohorts typically report worse symptoms and functional status than population based samples, our data suggest that many measures of symptom severity and functional impact are similar, and sometimes worse, in the RAND Interstitial Cystitis Epidemiology cohort. These findings suggest that interstitial cystitis/bladder pain syndrome is significantly burdensome, and likely to be underdiagnosed and undertreated in the United States.

Key Words:  cystitis , interstitial , epidemiology , prevalence , questionnaires

Abbreviations and Acronyms:  CC, clinical cohort , IC/BPS, interstitial cystitis/bladder pain syndrome , ICPI, Interstitial Cystitis Problem Index , ICSI, Interstitial Cystitis Symptom Index , RICE, RAND Interstitial Cystitis Epidemiology , RICE I, RICE high sensitivity , RICE II, RICE high specificity , SF-36®, short form health survey

 

 Study received institutional review board approval (RAND IRB # b4822-04-01).

 Supported by National Institute of Diabetes and Digestive and Kidney Diseases Grant UO1 DK070234.

 See Editorial on page 381.

 For other articles on a related topic see pages 715 and 725.

PII: S0022-5347(11)05284-0

doi:10.1016/j.juro.2011.10.040

The Journal of Urology
Volume 187, Issue 2 , Pages 508-512, February 2012